Replimune Group (REPL) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Replimune Group (REPL) is Neutral.

The composite score behind that read is +0.08, weighing +0.15 of bullish evidence against -0.24 bearish.

Replimune Group last closed at $13.42, +2.91% on the session.

Against the IVW growth benchmark the position is +2.11% over the forecast window.

The read is built from 15 underlying insights — 6 bullish and 9 bearish.

Agreement across those insights is 60%.

2 graded predictions for REPL so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Replimune Group in the 7th percentile on return on equity, where 100 is best.

Replimune Group is classified under Health Care / Biotechnology, with a market capitalisation of $1.23B.

StockMap tracks Replimune Group as the 122nd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Replimune Group ranks 55th of 381 in the group, against a group median of -0.08.